Daniel Grau, Avilar CEO
An RA-backed startup 'ATACs' a novel challenge, looking to spur protein degradation outside the cell
Protein degradation is one of the hot drug classes of the future, but competitors are piling in with the likes of C4, Arvinas, Frontier Medicines …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
